Immunotherapies using engineered T cells have ushered in a new era in cancer treatment, but they have their limits. They may cause side effects or stop working, and they do not work at all against 90% of cancers.
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients – Pharmaceutical Technology
The approval allows certain patients to receive Enhertu earlier in their treatment course. Credit: FatCamera via Getty Images. AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC)
January 29, 2025